中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2014年
12期
2673-2675
,共3页
王新君%白培明%鲁华东%廖洪锋%赵晓昆%罗广承
王新君%白培明%魯華東%廖洪鋒%趙曉昆%囉廣承
왕신군%백배명%로화동%료홍봉%조효곤%라엄승
肾透明细胞癌%丙酮酸激酶M2亚型
腎透明細胞癌%丙酮痠激酶M2亞型
신투명세포암%병동산격매M2아형
Clear cell renal cell carcinoma%Pyruvate kinase type M2
目的 探讨丙酮酸激酶M2亚型(PKM2)在肾透明细胞癌组织及癌旁组织中的表达及临床意义.方法 收集48例肾透明细胞癌组织及其配对的癌旁组织,采用Western blot和实时荧光定量聚合酶链反应(FQ-PCR)及免疫组织化学的方法检测PKM2在肾透明细胞癌组织和配对癌旁组织中的表达水平,并分析其表达水平与肾透明细胞癌临床病理特征的关系.结果 Westernblot和FQ-PCR结果提示:肾透明细胞癌组织中PKM2蛋白的相对表达量为1.585±0.112,癌旁组织的相对表达量为0.760±0.097.肾透明细胞癌组织中PKM2 mRNA的相对表达量为5.060±0.471,癌旁组织的相对表达量为3.431±0.221.免疫组织化学提示:PKM2的阳性染色颗粒主要位于细胞质内,PKM2在28例肾透明细胞癌组织中高表达(58.33%),在癌旁组织中仅5例高表达(10.41%),提示PKM2在肾透明细胞癌组织的表达强度明显高于癌旁组织,差异均有统计学意义(P<0.05).PKM2在肾透明细胞癌组织中的表达,随Fuhrman分级和TNM分期的增高,有升高趋势.结论 PKM2在肾透明细胞癌组织中高表达,其表达随病理分级和临床分级的的升高呈升高趋势,PKM2可能在肾透明细胞癌的发生、发展中起重要作用.
目的 探討丙酮痠激酶M2亞型(PKM2)在腎透明細胞癌組織及癌徬組織中的錶達及臨床意義.方法 收集48例腎透明細胞癌組織及其配對的癌徬組織,採用Western blot和實時熒光定量聚閤酶鏈反應(FQ-PCR)及免疫組織化學的方法檢測PKM2在腎透明細胞癌組織和配對癌徬組織中的錶達水平,併分析其錶達水平與腎透明細胞癌臨床病理特徵的關繫.結果 Westernblot和FQ-PCR結果提示:腎透明細胞癌組織中PKM2蛋白的相對錶達量為1.585±0.112,癌徬組織的相對錶達量為0.760±0.097.腎透明細胞癌組織中PKM2 mRNA的相對錶達量為5.060±0.471,癌徬組織的相對錶達量為3.431±0.221.免疫組織化學提示:PKM2的暘性染色顆粒主要位于細胞質內,PKM2在28例腎透明細胞癌組織中高錶達(58.33%),在癌徬組織中僅5例高錶達(10.41%),提示PKM2在腎透明細胞癌組織的錶達彊度明顯高于癌徬組織,差異均有統計學意義(P<0.05).PKM2在腎透明細胞癌組織中的錶達,隨Fuhrman分級和TNM分期的增高,有升高趨勢.結論 PKM2在腎透明細胞癌組織中高錶達,其錶達隨病理分級和臨床分級的的升高呈升高趨勢,PKM2可能在腎透明細胞癌的髮生、髮展中起重要作用.
목적 탐토병동산격매M2아형(PKM2)재신투명세포암조직급암방조직중적표체급림상의의.방법 수집48례신투명세포암조직급기배대적암방조직,채용Western blot화실시형광정량취합매련반응(FQ-PCR)급면역조직화학적방법검측PKM2재신투명세포암조직화배대암방조직중적표체수평,병분석기표체수평여신투명세포암림상병리특정적관계.결과 Westernblot화FQ-PCR결과제시:신투명세포암조직중PKM2단백적상대표체량위1.585±0.112,암방조직적상대표체량위0.760±0.097.신투명세포암조직중PKM2 mRNA적상대표체량위5.060±0.471,암방조직적상대표체량위3.431±0.221.면역조직화학제시:PKM2적양성염색과립주요위우세포질내,PKM2재28례신투명세포암조직중고표체(58.33%),재암방조직중부5례고표체(10.41%),제시PKM2재신투명세포암조직적표체강도명현고우암방조직,차이균유통계학의의(P<0.05).PKM2재신투명세포암조직중적표체,수Fuhrman분급화TNM분기적증고,유승고추세.결론 PKM2재신투명세포암조직중고표체,기표체수병리분급화림상분급적적승고정승고추세,PKM2가능재신투명세포암적발생、발전중기중요작용.
Objective To investigate the expression of pyruvate kinase type M2 (PKM2) in human clear cell renal cell carcinoma tissues with regard to related clinicopathologic significance.Methods 48 cases of clear cell renal cell carcinoma tissues and matched normal adjacent tissues were collected.The expression of PKM2 was detected by immunohistochemistry,Western blotting and real-time fluorescent quantitative polymerase chain reaction (FQ-PCR).The relationship between clinicopathologic parameters and PKM2 expression was analyzed.Results The relative expression of PKM2 protein and mRNA in Clear cell renal cell carcinoma tissues are 1.585 ± 0.112 and 5.060 ± 0.471 by Western blotting and FQ-PCR respectively.And the relative expression of PKM2 protein and mRNA in matched adjacent normal kidney tissues are 0.760 ±0.097 and 3.431-±0.221.By immunohistochemistry,PKM2 protein mainly stained in the cytoplasm.High expression of PKM2 were noticed in 28 clear cell renal cell carcinoma tissues,accounting for 58.33%.In adjacent normal kidney tissues,only 5 cases showed high expression,accounting for 10.41%.And the differences are statistically significant.Higher PKM2 expression was associated with higher clinical stage and pathological grade.Conclusion PKM2 protein and mRNA have a significantly high expression in clear cell renal cell carcinoma tissues.PKM2 expression associated with tumor grade and pathological stage.PKM2 may be involved in the occurrence and progression of clear cell renal cell carcinoma.